Tetracosactide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Tetracosactide
   1. Pharmacist Assessment Report
   2. Tetracosactide: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Tetracosactide: Known uses and market status in Australia

Summary

All candidates that the TxGNN deep-learning model (score ≥ 0.99) produced for Tetracosactide and that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug. The one known use is recorded as a knowledge graph relation.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
Addison disease

Australia Market Information

Licence	Product	Dosage form	Status
2832C	Synacthen Depot 1 mg/1 mL	Compound depot injection 1 mg in 1 mL	Valid

Safety Considerations

Drug Interactions (100 interactions were identified; 20 are shown in the data compiled, mostly Moderate):

• Major: Bupropion
• Moderate (glucose-lowering agents): acarbose, albiglutide, alogliptin, metformin, canagliflozin, chlorpropamide, acetohexamide, dapagliflozin, dulaglutide, empagliflozin, ertugliflozin, exenatide
• Moderate (other): amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms), bisacodyl, picosulfuric acid, castor oil

Corticosteroid stimulation can raise blood glucose, which may account for the antidiabetic interactions. This is an inference, not stated in the data compiled.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, which were not available for this report.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---